Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement
Segments

Common Size IS
Op Efficiency
Credit Analysis

Global Blood Therapeutics, Inc. (GBT)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
  Older >>
In millions, except per share itemsDec-31-21Dec-31-20Dec-31-19Dec-31-18Dec-31-17Dec-31-16Dec-31-15Dec-31-14
   10-K10-K10-K10-K10-K10-K10-K10-K
Total revenues  194.7123.82.19.00.00.00.00.0
            Revenue growth  57.3%5773.0%-76.5%     
Cost of goods sold  3.32.00.00.10.00.00.00.0
Gross profit  191.4121.82.18.90.00.00.00.0
            Gross margin  98.3%98.4%97.7%99.2%    
Selling, general and administrative   [+]267.0210.9117.151.431.421.09.73.9
Research and development  212.1155.1174.6131.387.862.236.716.3
Other operating expenses   -1.0-8.38.9  0.10.3
EBITDA   [+]-281.8-234.8-272.7-178.1-117.6-82.0-45.5-19.8
            EBITDA margin  -144.7%-189.7%-12935.4%-1987.2%    
Depreciation and amortization  5.98.38.64.61.71.20.90.7
EBIT   [+]-287.7-243.2-281.3-182.7-119.2-83.1-46.4-20.5
            EBIT margin  -147.7%-196.4%-13343.6%-2038.6%    
Interest expense, net   [+]    -2.6-0.70.00.0
Other income (expense), net   [+]89.1-4.414.58.6-0.3  -0.3
Pre-tax income  -302.6-247.6-266.8-174.2-117.0-82.5-46.4-20.8
Income taxes  0.50.00.00.00.00.00.00.0
            Tax rate   0.0% 0.0%0.0%0.0%0.0%0.0%
Net income  -303.1-247.6-266.8-174.2-117.0-82.5-46.4-23.8
            Net margin  -155.6%-200.0%-12654.9%-1943.3%    
   
Basic EPS   [+]($4.81)($4.04)($4.57)($3.41)($2.76)($2.48)($3.62)($14.20)
Diluted EPS   [+]($4.81)($4.04)($4.57)($3.41)($2.76)($2.48)($3.62)($14.20)
   
Shares outstanding (basic)   [+]63.061.358.351.242.433.212.81.7
Shares outstanding (diluted)   [+]63.061.358.351.242.433.212.81.7
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy